期刊文献+

晚期非小细胞肺癌组织中LRP表达与铂类耐药性及预后的相关性研究 被引量:4

Study on correlation among expression of LRP and platinum resistance and prognosis in advanced non-small cell lung cancer
暂未订购
导出
摘要 目的探讨晚期非小细胞肺癌(NSCLC)组织中肺耐药蛋白(LRP)的表达与铂类化疗耐药及其预后的关系。方法采用免疫组织化学SP法对89例晚期NSCLC碏块进行免疫组织化学染色,检测LRP的表达水平,并分析其与患者的性别、年龄、吸烟史、组织分型、分化程度、远处转移、淋巴结转移及含铂化疗方案疗效的关系。结果在NSCLC患者组织中,LRP的阳性表达率为77.5%,与年龄、吸烟史、组织分型、分化程度和淋巴结转移无关(P均>0.05),而LRP表达阳性组和阴性组的含铂类方案化疗疗效、有效率、总反应率、无进展生存时间和总生存时间比较差异无统计学意义(P均>0.05)。女性患者肿瘤组织LRP表达阳性率(95.5%)高于男性患者(71.6%)(P=0.043);在远处转移的患者中,LPR阳性表达率为87.3%,而无远处转移的患者LRP阳性表达率为61.8%,差异有统计学意义(P=0.005)。结论 LRP基因的阳性表达与远处转移有关,且LRP阳性表达患者无疾病进展时间及总生存时间均低于LRP阴性表达患者,提示其可能作为判断预后指标。 Objective To study the expression of lung resistance protein (LRP) in non-small cell Lung Cancer(NSCLC) and its correlation with Platium resistance and prognosis .Methods The expression of LRP in 89 NSCLC patients was detected by the way of immunohistochemical method .The relationship between LRP and clinico-pathological feature and the others (age, sex, smoking history, histological type, differentiation, distant metastasis, lymphatic metastasis and so on ) were studied .Results In the tissues of patients with NSCLC , the positive express-ing rate of LRP was 77.5%, and was not related with age , sex, smoking history, histological type, differentiation, distant metastasis , lymphatic metastasis ( P〉0.05 ) .In the platinum contained chemotherapy regimens , there were not statistical significant difference in RR , DCR, PFS, and OS between the LRP positive expression group and the LRP negative expression group ( all P〉0.05 ) .The positive expression rate of LRP in female patients ( 95.5%) was higher than that in male patients(71.6%;P=0.043).The positive expression rate in the patient with distant metas-tasis(87.3%) was higher than that in the patients without distant metastasis (61.8%)(P=0.005).Conclusion The positive expression of LRP is related to the diagnosis distant metastasis of NSCLC .The PFS, OS in LRP-positive patients are lower than those in LRP negative patients .These results suggest LRP may be an evaluating indicator of the prognosis of NSCLC .
出处 《中国临床新医学》 2014年第1期1-4,共4页 CHINESE JOURNAL OF NEW CLINICAL MEDICINE
基金 广西自然科学基金资助项目(编号:2010GXNSFA013260) 南宁市科学研究与技术开发计划项目(编号:201003045C-6)
关键词 非小细胞肺癌 肺耐药蛋白 顺铂 耐药 预后 Platinum Drug resistanc Prognosis
  • 相关文献

参考文献5

二级参考文献36

  • 1辛华雯,王润帮.MTT显色法快速测定实体瘤化疗药物敏感性的方法研究[J].肿瘤防治研究,1993,20(4):254-256. 被引量:26
  • 2颜笑健,梁立治,曾宗渊,刘继红,袁颂华,魏梅.铂类化疗敏感型卵巢上皮癌复发的影响因素[J].癌症,2005,24(6):751-754. 被引量:14
  • 3李文锦,颜士杰,钱和年,张香云,王建六,李小平,宋和存,贾鉴慧,林文玉.卵巢粘液性囊腺癌EGFR、neu、PCNA的表达与临床病理研究[J].浙江肿瘤,1996,2(2):67-69. 被引量:3
  • 4Xiao-Yun Mao,Xiao-Ge Wang,Xiao-Jun Lv,Lei Xu,Cheng-Bo Han.COX-2 expression in gastric cancer and its relationship with angiogenesis using tissue microarray[J].World Journal of Gastroenterology,2007,13(25):3466-3471. 被引量:46
  • 5Brinkhuis M, Izquierdo M A, Baak J P, et al. Expression of muhidrug resistance-associated markers, their relation to quantitative athologic tumor characteristics and prognosis in advanced ovarian cancer [J]. Anal Cell Pathol, 2002,24( 1): 17-23.
  • 6Izquierdo M A, van der Zee A G, Vermorken J B, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma [J]. Natl Cancer Inst, 1995,87(16) : 1230-1237.
  • 7Arts H J, Katsaros D, de Vries E G, et al. Drug resistanceassociated markers P-glycoprotein, muhidrug resistancassociated protein 1, muhidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma [ J]. Clin Cancer Res, 1999,5 (10) : 2798-2805.
  • 8Gross M E, Shazer R L, Agus D B. Targeting the HER- kinaseaxisin cancer [ J ]. Semin Oncol, 2004,31 (13) : 9-20.
  • 9Park S J, Armstrong S, Kim C H, et al. Lack of EGF receptor contributes to drug sensitivity of human germline ceils [J]. Br J Cancer, 2005,92(2) : 334-341.
  • 10Coley H M, Shotton C F, Ajose-Adeogun A, et al. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents [J]. Biochem Pharmacol, 2006,72(8) :941-948.

共引文献28

同被引文献38

引证文献4

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部